Drug Trial Radar · NCT01169259
Vitamin D and Omega-3 Trial (VITAL)
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25,871
Actual
Start
Jul 2010
Primary completion
Nov 10, 2018
Study completion Mar 2031
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements (ODS); National Institute of Neurological Disorders and Stroke (NINDS); National Center for Complementary and Integrative Health (NCCIH); Pharmavite LLC; Pronova BioPharma; BASF
- First posted
- Jul 26, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The 5-year intervention phase (study pill-taking, median 5.3 years) has ended; post-intervention observational follow-up of study participants is ongoing.
Conditions
- Cancer
- Cardiovascular Disease
Interventions
vitamin D3Dietary supplement
Vitamin D3 (cholecalciferol), 2000 IU per day.
omega-3 fatty acids (fish oil)Drug
Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Vitamin D3 placeboDietary supplement
Vitamin D placebo
Fish oil placeboDietary supplement
Fish oil placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Invasive Cancer of Any TypeTime frame: 5 years
- Number of Participants With a Major Cardiovascular EventTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.